Brokerages Set GSK plc (LON:GSK) Price Target at GBX 1,805.83

GSK plc (LON:GSK) has earned an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is GBX 1,805.83 ($22.10).

A number of equities analysts recently issued reports on GSK shares. Berenberg Bank lowered their price target on GSK from GBX 1,820 ($22.27) to GBX 1,600 ($19.58) and set a “buy” rating on the stock in a report on Friday, November 29th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Tuesday, January 7th.

GSK Stock Performance

LON GSK opened at GBX 1,372 ($16.79) on Tuesday. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04. GSK has a 52-week low of GBX 1,282.50 ($15.69) and a 52-week high of GBX 1,823.50 ($22.31). The business’s 50-day moving average price is GBX 1,345.40 and its 200 day moving average price is GBX 1,472.36. The firm has a market cap of £55.98 billion, a P/E ratio of 1,214.16, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK Announces Dividend

The firm also recently disclosed a dividend, which was paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th were issued a GBX 15 ($0.18) dividend. This represents a yield of 1.03%. The ex-dividend date of this dividend was Thursday, November 14th. GSK’s dividend payout ratio is presently 5,309.73%.

Insider Buying and Selling at GSK

In other news, insider Jonathan Symonds purchased 1,500 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were acquired at an average price of GBX 1,315 ($16.09) per share, with a total value of £19,725 ($24,134.34). In the last 90 days, insiders have acquired 8,658 shares of company stock valued at $11,950,792. 1.61% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.